Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease

BACKGROUND AND OBJECTIVES: Use of parenteral amikacin to treat refractory nontuberculous mycobacterial (NTM) lung disease is limited by systemic toxicity. A population pharmacokinetic model was developed using data pooled from two randomized trials to evaluate the pharmacokinetic properties of once-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur J Drug Metab Pharmacokinet
Autors principals: Rubino, Christopher M., Onufrak, Nikolas J., van Ingen, Jakko, Griffith, David E., Bhavnani, Sujata M., Yuen, Dayton W., Mange, Kevin C., Winthrop, Kevin L.
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2021
Matèries:
Original Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7935831/
https://ncbi.nlm.nih.gov/pubmed/33595792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13318-020-00669-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars